GET 73 is an investigational new drug, developed by Laboratorio Farmaceutico CT SRL, that is being evaluated for treating alcohol use disorder (AUD). It acts as a negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5), a receptor system implicated in the neurobiology of addiction and alcohol-related behaviors. Preclinical studies indicate that GET 73 reduces voluntary alcohol intake, diminishes the alcohol deprivation effect, and demonstrates neuroprotective properties against alcohol-induced neurotoxicity in animal models. It has also been evaluated in early-phase human trials for safety and potential efficacy in reducing alcohol craving and consumption. GET 73 is a more structurally complex analog of GHB.
References
Further reading


